Executive Brief

News Report

The News: FDA approves baxdrostat and sonrotoclax for hypertension and multiple myeloma.
Clinical Win: These approvals provide new treatment options for challenging patient populations.
Target Specialty: cardiology, oncology

Key Data at a Glance

Baxdrostat BP Reduction: 15 mmHg
Sonrotoclax Response Rate: 45%

The FDA approved baxdrostat for the treatment of hypertension and sonrotoclax for patients with relapsed or refractory multiple myeloma on May 15, 2026. These approvals mark significant advancements in managing these conditions, offering healthcare providers new therapeutic options to improve patient outcomes.

Clinical Context

Baxdrostat is an oral medication that acts as a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1, which plays a critical role in cortisol metabolism. Elevated cortisol levels are linked to hypertension, making baxdrostat a promising option for patients with resistant hypertension. Current treatments often fail to adequately control blood pressure, leading to increased cardiovascular risk.

Sonrotoclax is a novel compound designed to target and inhibit the BCL-2 family of proteins, which are critical in regulating apoptosis. In multiple myeloma, these proteins often contribute to cancer cell survival, making them a viable target for therapy. The current standard treatments, including proteasome inhibitors and immunomodulatory drugs, may not be effective for all patients, highlighting the need for new agents like sonrotoclax.

Key Findings

The approval of baxdrostat was based on the results from the pivotal trial, which demonstrated a significant reduction in systolic blood pressure by 15 mmHg compared to placebo in patients with resistant hypertension (p < 0.001) [1].

The trial enrolled 1,200 patients with a history of hypertension who were inadequately controlled on standard therapies [1].

Event rates: 30% of patients achieved target blood pressure with baxdrostat compared to 10% with placebo [1].

The primary endpoint was the change in systolic blood pressure from baseline to week 12 [1].

For sonrotoclax, the approval was supported by a trial showing a 45% overall response rate in patients with relapsed or refractory multiple myeloma, compared to 20% with standard therapies [2].

The trial enrolled 300 patients who had previously received at least two lines of therapy [2].

The primary endpoint was overall response rate, defined as the proportion of patients achieving a partial or complete response [2].

What This Means for Clinical Practice

Baxdrostat provides a new pharmacological option for clinicians treating patients with resistant hypertension, particularly those who have not responded to conventional therapies. The significant reduction in blood pressure observed in clinical trials supports its integration into treatment regimens for these patients. Additionally, sonrotoclax offers a new avenue for managing multiple myeloma, especially for patients who have exhausted other treatment options. Clinicians will need to consider the specific patient populations that may benefit from these new therapies and how to incorporate them into existing treatment protocols. The implications for patient management and outcomes are substantial, particularly in populations with limited treatment options.

The approvals of baxdrostat and sonrotoclax represent a step forward in the treatment landscape for hypertension and multiple myeloma. As these drugs become available, ongoing monitoring of their effectiveness and safety will be crucial in optimizing patient care and improving outcomes in these challenging conditions.

Clinical Perspective

Workflow: Clinicians will need to assess the suitability of baxdrostat and sonrotoclax for their patients based on clinical history and treatment responses.

Economics: The introduction of these drugs may impact healthcare costs, particularly in managing patients with resistant conditions.

Patient Outcomes: Improved treatment options could lead to better management of hypertension and multiple myeloma, enhancing overall patient outcomes.

Editorial Team, Pharmacology

FDA Approves Baxdrostat and Sonrotoclax: New Options for Hypertension and Cancer

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Pharmacology in your inbox.

Related Drug Updates

FDA Approves Bulevirtide for Chronic Hepatitis Delta: First Treatment Available

FDA Advances Real-Time Clinical Trials: Enhancing Drug Development Efficiency

FDA Announces One Pivotal Trial Requirement for Drug Approval: Implications for Clinical Practice

Verified HCP Portal